Claims for Patent: 10,105,415
✉ Email this page to a colleague
Summary for Patent: 10,105,415
Title: | Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease |
Abstract: | The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and fosfomycin for the treatment, prevention or alleviation of an inflammatory bowel disease such as Crohn\'s disease, ulcerative colitis or necrotizing enterocolitis of newborn and premature infants by administration of the compositions into the intestinal lumen. |
Inventor(s): | Heslet; Lars (Gentofte, DK), Uttenthal; Lars Otto (Salamanca, ES) |
Assignee: | Reponex Pharmaceuticals A/S (Horsholm, DK) |
Application Number: | 15/328,426 |
Patent Claims: | 1. A method of alleviating the symptoms of inflammatory bowel disease, comprising: selecting a patient that has inflammatory bowel disease; administering to said
selected patient locally into a bowel lumen an effective amount of a composition comprising a granulocyte-macrophage colony-stimulating factor (GM-CSF), molgramostim or sargramostim, fosfomycin and metronidazole.
2. The method of alleviating the symptoms of the inflammatory bowel disease according to claim 1, wherein said inflammatory bowel disease is any one of Crohn's disease, ulcerative colitis or necrotizing enterocolitis. 3. The method of alleviating the symptoms of the inflammatory bowel disease according to claim 2, wherein said inflammatory bowel disease is ulcerative colitis and wherein the composition is for local administration into the lumen of an affected area of any one of the ascending, transverse, descending and sigmoid colon or rectum. 4. The method of alleviating the symptoms of the inflammatory bowel disease according to claim 2, wherein said inflammatory bowel disease is necrotizing enterocolitis in a newborn or premature infant and wherein the composition is for local administration into the lumen of an affected area of any one of the ascending, transverse, descending and sigmoid colon or rectum. 5. The method of alleviating the symptoms of the inflammatory bowel disease according to claim 4, wherein the GM-CSF is in a formulation comprising liposome or micelle or microcapsule or nanoparticle. 6. The method of alleviating the symptoms of the inflammatory bowel disease according to claim 5, wherein the composition further comprises one or more protease inhibitors suitable for in-vivo administration into the bowel lumen. 7. The method of alleviating the symptoms of the inflammatory bowel disease according to claim 6, wherein the one or more protease inhibitors is aprotinin and/or soybean trypsin inhibitor. 8. The method of alleviating the symptoms of the inflammatory bowel disease according to claim 7, wherein the GM-CSF comprises a conjugate that extends the half-life of the active ingredient. 9. The method of alleviating the symptoms of the inflammatory bowel disease according to claim 7, wherein the conjugate that extends the half-life of the active ingredient is albumin or a fatty acid. 10. The method of alleviating the symptoms of the inflammatory bowel disease according to claim 2, wherein said inflammatory bowel disease is Crohn's disease, and wherein the composition is for local administration into the lumen of an affected area of the intestines. |
Details for Patent 10,105,415
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bayer Healthcare Pharmaceuticals Inc. | TRASYLOL | aprotinin | Injection | 020304 | 12/29/1993 | ⤷ Try a Trial | 2034-07-24 |
Partner Therapeutics, Inc. | LEUKINE | sargramostim | For Injection | 103362 | 03/05/1991 | ⤷ Try a Trial | 2034-07-24 |
Partner Therapeutics, Inc. | LEUKINE | sargramostim | Injection | 103362 | 03/05/1991 | ⤷ Try a Trial | 2034-07-24 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.